The high cost of prescription drugs in the United States creates a barrier to access and treatment for millions of Americans. Discussions with policymakers have stretched on for many years about how to address this issue. While the passage of the Inflation Reduction Act of 2022 has been hailed as significant progress toward lowering drug costs, efforts to secure additional reforms will continue so patients can afford the care and treatment they need.
The Inflation Reduction Act included a number of policy reforms that will dramatically reshape how prescription drugs are paid for in the United States. This law allows the Secretary of Health and Human Services to negotiate the price of drugs in Medicare for the first time. It also limits what senior citizens and other Medicare beneficiaries pay out of their own pocket for pharmaceuticals.
Throughout the debate around the Inflation Reduction Act and policy proposals that preceded it, Pyxis Partners used a combination of intensive policy analysis, strategic communications, and trusted relationships to advise clients on how to achieve their policy goals pertaining to the cost of prescription drugs. This comprehensive approach resulted in a winning hand for our partners.
Now, as Congress and the Biden-Harris administration seek additional reforms to lower the cost of prescription drugs, Pyxis Partners will continue our efforts; ensuring clients have access to the policy and political intelligence they need to make informed decisions, as well as securing them a seat at the table as decisions are made.